183 related articles for article (PubMed ID: 1750430)
1. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.
Armitage JO; Bierman PJ; Vose JM; Anderson JR; Weisenburger DD; Kessinger A; Reed EC; Vaughan WP; Coccia PF; Purtilo DT
Am J Med; 1991 Dec; 91(6):605-11. PubMed ID: 1750430
[TBL] [Abstract][Full Text] [Related]
2. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant.
Crump M; Smith AM; Brandwein J; Couture F; Sherret H; Sutton DM; Scott JG; McCrae J; Murray C; Pantalony D
J Clin Oncol; 1993 Apr; 11(4):704-11. PubMed ID: 8478664
[TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
[TBL] [Abstract][Full Text] [Related]
5. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Linch DC; Winfield D; Goldstone AH; Moir D; Hancock B; McMillan A; Chopra R; Milligan D; Hudson GV
Lancet; 1993 Apr; 341(8852):1051-4. PubMed ID: 8096958
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
[TBL] [Abstract][Full Text] [Related]
7. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients.
Chopra R; McMillan AK; Linch DC; Yuklea S; Taghipour G; Pearce R; Patterson KG; Goldstone AH
Blood; 1993 Mar; 81(5):1137-45. PubMed ID: 8443375
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease.
Spinolo JA; Jagannath S; Velásquez W; Spitzer G; Cabanillas F; Hagemeister F; Horwitz LJ; Dicke KA
Leuk Lymphoma; 1993 Jan; 9(1-2):71-7. PubMed ID: 8477204
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
[TBL] [Abstract][Full Text] [Related]
10. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: an Italian study group report.
Carella Am; Carlier P; Congiu A; Occhini D; Meloni G; Anselmo AP; Mandelli F; Mazza P; Tura S; Mangoni L
Leukemia; 1991; 5 Suppl 1():68-71. PubMed ID: 1890870
[TBL] [Abstract][Full Text] [Related]
11. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
12. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
[TBL] [Abstract][Full Text] [Related]
13. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group.
Tsang RW; Gospodarowicz MK; Sutcliffe SB; Crump M; Keating A
Eur J Cancer; 1999 Jan; 35(1):73-8. PubMed ID: 10211091
[TBL] [Abstract][Full Text] [Related]
14. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
Seymour LK; Dansey RD; Bezwoda WR
Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of resistant or relapsing Hodgkin's disease with high doses of chemotherapy followed by autologous bone marrow transplant].
Domingo-Albós A; García J; Puig J; Brunet S; Ayats R; Pardo N; Soler J; Muñiz E; Badell I
Med Clin (Barc); 1990 Mar; 94(9):321-4. PubMed ID: 2329865
[TBL] [Abstract][Full Text] [Related]
16. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.
Desch CE; Lasala MR; Smith TJ; Hillner BE
J Clin Oncol; 1992 Feb; 10(2):200-9. PubMed ID: 1531067
[TBL] [Abstract][Full Text] [Related]
17. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
Yahalom J; Gulati S
Ann Oncol; 1991 Feb; 2 Suppl 2():67-71. PubMed ID: 2049322
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation in Hodgkin's disease.
Gisselbrecht C; Brice P; Lepage E; Brichon P; Gerota J; Boiron M
Nouv Rev Fr Hematol (1978); 1990; 32(1):5-7. PubMed ID: 2190180
[TBL] [Abstract][Full Text] [Related]
20. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
